DeepMed Research

UNIVERSITY OF ILLINOIS

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1859-01-01

Employees: 10K

Market Cap: -

Website: http://www.illinois.edu

Clinical Trials

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

Phase 2

Recruiting

Conditions: Corneal Ulcer

Interventions: Biological: Mesenchymal Stromal Cells
Other: Control Solution

First Posted Date: 2023-01-30

Last Posted Date: 2024-11-25

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 38

Registration Number: NCT05705024

Locations: 🇺🇸
Department of Ophthalmology and Visual Sciences, Chicago, Illinois, United States
🇺🇸
University of Maryland at Baltimore, Baltimore, Maryland, United States
🇺🇸
Mass Eye and Ear Infirmary, Boston, Massachusetts, United States

and more 1 locations

Implementation of Population Breast Cancer Genetic Services in Federally Qualified Health Centers (FQHC)

Not Applicable

Withdrawn

Conditions: Hereditary Cancer Syndrome

Interventions: Other: Mainstream Genetic Testing Model
Other: Enhanced Standard of Care Model

First Posted Date: 2022-12-27

Last Posted Date: 2023-09-13

Lead Sponsor: University of Illinois at Chicago

Registration Number: NCT05664867

The PIVOT Trial: Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older

Not Applicable

Recruiting

Conditions: Type2diabetes
Obesity
Dyslipidemias
CARDIOMETABOLIC CONDITIONS
Pre-diabetes
Hypertension
Metabolic Syndrome

Interventions: Behavioral: Base intervention
Behavioral: Augmented Intervention

First Posted Date: 2022-12-16

Last Posted Date: 2024-12-11

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 1029

Registration Number: NCT05654142

Locations: 🇺🇸
Department of Medicine, Vitoux Program on Aging and Prevention, Chicago, Illinois, United States
🇺🇸
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
🇺🇸
Washington University School of Medicine in St Louis, Saint Louis, Missouri, United States

Testing Self-Directed Care in Florida

Not Applicable

Completed

Conditions: Mental Disorder

Interventions: Behavioral: Services as usual
Behavioral: Self-Directed Care

First Posted Date: 2022-12-14

Last Posted Date: 2023-05-09

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 42

Registration Number: NCT05649449

Locations: 🇺🇸
University of Illinois at Chicago, Department of Psychiatry, Chicago, Illinois, United States

Enhancing Immune Health Randomized Controlled Trial

Not Applicable

Recruiting

Conditions: Mental Disorder

Interventions: Behavioral: Enhancing Your Immune Health

First Posted Date: 2022-12-06

Last Posted Date: 2024-12-05

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 100

Registration Number: NCT05639881

Locations: 🇺🇸
University of Illinois Chicago, Chicago, Illinois, United States

Time Restricted Eating for the Treatment of PCOS

Not Applicable

Completed

Conditions: Polycystic Ovary Syndrome
Obesity
Overweight

Interventions: Other: Control
Other: 6-h Time restricted eating (TRE)
Other: Calorie restriction (CR)

First Posted Date: 2022-11-29

Last Posted Date: 2025-03-13

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 76

Registration Number: NCT05629858

Locations: 🇺🇸
University of Illinois Chicago, Chicago, Illinois, United States

Dilution of Verapamil During Intraarterial Administration

Early Phase 1

Completed

Conditions: Vasospasm;Peripheral
Burning
Pain

Interventions: Drug: Verapamil
Drug: Nicardipine

First Posted Date: 2022-11-23

Last Posted Date: 2024-11-27

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 55

Registration Number: NCT05625503

Locations: 🇺🇸
University of Illinois Hospital, Chicago, Illinois, United States

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Phase 2

Recruiting

Conditions: Metastatic Squamous Non-Small Cell Lung Carcinoma

Interventions: Drug: Cabozantinib 40 MG
Drug: Pembrolizumab 200mg
Drug: Pembrolizumab 400mg

First Posted Date: 2022-11-14

Last Posted Date: 2025-02-03

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 36

Registration Number: NCT05613413

Locations: 🇺🇸
Ryan Nguyen, Chicago, Illinois, United States

Feasibility of Implementing Acupuncture Into Federally Qualified Health Center Among Breast Cancer Survivors

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Acupuncture

First Posted Date: 2022-11-14

Last Posted Date: 2025-03-30

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 62

Registration Number: NCT05615753

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

Study of a PST-Trained Voice-Enabled Artificial Intelligence Counselor(SPEAC) for Adults With Emotional Distress (Phase 2)

Not Applicable

Active, not recruiting

Conditions: Anxiety
Depression

Interventions: Behavioral: Lumen Coached PST Intervention.
Behavioral: Human Coached PST Intervention.
Behavioral: Optional (delayed) Lumen Coached PST (Waitlist control).

First Posted Date: 2022-11-03

Last Posted Date: 2025-01-08

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 200

Registration Number: NCT05603923

Locations: 🇺🇸
Department of Medicine, Vitoux Program on Aging and Prevention, Chicago, Illinois, United States
🇺🇸
UIMC Advanced Imaging Center, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy